<DOC>
	<DOCNO>NCT00740285</DOCNO>
	<brief_summary>Scleroderma , systemic sclerosis , chronic connective tissue disease generally classify one autoimmune rheumatic disease . The disease characterize thicken fibrosis skin , affect vessel many organ esophagus , stomach , bowl , lung , heart kidney . The exact cause cause scleroderma still unknown , scientist medical investigator wide variety field work hard make determination . It known scleroderma involve overproduction collagen . FLICKMAN et al , 1973 publish article role lidocaine prolyl-hydroxylase activity decrease , important enzyme collagen production . Until , case series show improvement thicken skin ( 75 % ) esophagus symptom ( 66 % ) intravenous lidocaine 2 % 10 day . So necessary RCT prove finding .</brief_summary>
	<brief_title>Effectiveness Safety Lidocaine Scleroderma</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>Scleroderma ( diffuse limit ) less 5 year first symptom Overlap connective tissue disease Fibromyalgia Pregnancy Current use ciclofosfamide ou Dpenicillamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>scleroderma</keyword>
	<keyword>scleroderma - limited diffuse type</keyword>
	<keyword>lidocaine</keyword>
	<keyword>effectiveness</keyword>
</DOC>